我们最近报道,外消旋5,11-顺二乙基-5,6,11,12-四氢丙烯-2,8-二醇(THC,rac-2b)充当雌激素受体α(ERalpha)的激动剂和雌激素受体β(ERbeta)的完全拮抗剂(Sun et al。Endocrinology 1999,140,800-804)。为了进一步研究这种新颖的ER亚型选择性雌激素活性,我们合成了一系列顺式和反式二烷基四氢大麻酚。通过对映体纯的α-烷基-β-芳基丙酸酯的酰基糊精缩合,然后在温度下,在路易斯酸介导的双环化下,以高度对映和非对映选择性的方式制备顺式-二甲基,-二乙基和-二丙基THC 2a-c。最小差向异构的条件。ERalpha和ERbeta的顺式和反式异构体的二甲基,二乙基,在竞争性结合试验中测定了二丙基四氢大麻酚的含量,在哺乳动物细胞中通过报道基因测定了它们的转录活性。发现几乎所有检查的THC对ERbeta都具有亲和力。所有这些THC都是
我们最近报道,外消旋5,11-顺二乙基-5,6,11,12-四氢丙烯-2,8-二醇(THC,rac-2b)充当雌激素受体α(ERalpha)的激动剂和雌激素受体β(ERbeta)的完全拮抗剂(Sun et al。Endocrinology 1999,140,800-804)。为了进一步研究这种新颖的ER亚型选择性雌激素活性,我们合成了一系列顺式和反式二烷基四氢大麻酚。通过对映体纯的α-烷基-β-芳基丙酸酯的酰基糊精缩合,然后在温度下,在路易斯酸介导的双环化下,以高度对映和非对映选择性的方式制备顺式-二甲基,-二乙基和-二丙基THC 2a-c。最小差向异构的条件。ERalpha和ERbeta的顺式和反式异构体的二甲基,二乙基,在竞争性结合试验中测定了二丙基四氢大麻酚的含量,在哺乳动物细胞中通过报道基因测定了它们的转录活性。发现几乎所有检查的THC对ERbeta都具有亲和力。所有这些THC都是
Asymmetric Hydrogenation of α,β-Unsaturated Carboxylic Acids Catalyzed by Ruthenium(II) Complexes of Spirobifluorene Diphosphine (SFDP) Ligands
作者:Xu Cheng、Jian-Hua Xie、Sheng Li、Qi-Lin Zhou
DOI:10.1002/adsc.200606065
日期:2006.7
The ruthenium diacetate complexes ligated by chiral spirobifluorene diphosphines (SFDP) were very effective catalysts for the asymmetric hydrogenation of tiglic acid derivatives and α-methylcinnamic acid derivatives with high activities and excellent enantioselectivities (up to 98 % ee). The α-aryloxybutenoic acids can also be hydrogenated by these catalysts to provide the corresponding saturated α-aryloxybutanoic
IDENTIFICATION OF COMPOUNDS MODIFYING A CELLULAR RESPONSE
申请人:Thastrup Ole
公开号:US20130123140A1
公开(公告)日:2013-05-16
The present invention relates to methods for identifying compounds capable of modulating a cellular response. The methods involve attaching living cells to solid supports comprising a library of test compounds. The test compounds are linked to the solid support via cleavable linkers and may thus be released from the solid supports. Solid supports comprising cells, wherein the cellular response of interest has been modulated are selected and the test compound of the solid support can then be identified. The cellular response may for example be changes in complex formation between proteins.
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I:
where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.